The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...

The drug has also been evaluated in adults and adolescents. Following the positive data, Novo Nordisk expects to make its Mim8 regulatory submission in 2025. Haemophilia A is a rare blood disorder ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.